Related Experiment Video
Updated: Sep 11, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Design, Synthesis, and Biological Evaluation of Triazolopyrimidine-Isatin Hybrids as Promising Candidates for
Shefali Chowdhary1, Asif Raza2, Natacha Henry3
1Department of Chemistry, Guru Nanak Dev University, Amritsar, India.
Abstract:
Triple-negative breast cancer (TNBC) is a highly aggressive subtype marked by pronounced intra-tumoral heterogeneity and frequent therapeutic resistance. In this study, we report the design, synthesis, and biological evaluation of a novel series of triazolopyrimidine-isatin hybrids against the TNBC cell lines MDA-MB-231 and MDA-MB-468. Among them, 9h emerged as the most promising candidate, exhibiting potent cytotoxic activity against TNBC cell lines. Notably, 9h demonstrated 5.7-fold greater potency than tamoxifen and slightly better efficacy than the reference drug cisplatin against MDA-MB-231 cells. Further, 9h induced a significant reduction in MDA-MB-231 cell viability through caspase-mediated apoptosis. Preliminary ADMET predictions were also carried out to assess pharmacokinetic properties.
Insights
Researchers developed new triazolopyrimidine-isatin compounds to treat triple-negative breast cancer (TNBC). Compound 9h showed strong cytotoxic activity against TNBC cells, inducing apoptosis and demonstrating potential as a novel therapeutic agent.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive cancer subtype.
- TNBC is characterized by significant intra-tumoral heterogeneity and resistance to therapies.
- Novel therapeutic strategies are urgently needed for TNBC treatment.
Purpose of the Study:
- To design, synthesize, and evaluate novel triazolopyrimidine-isatin hybrids as potential anti-TNBC agents.
- To identify lead compounds with potent cytotoxic activity against TNBC cell lines.
- To investigate the mechanism of action and preliminary pharmacokinetic properties of promising candidates.
Main Methods:
- Synthesis of a series of triazolopyrimidine-isatin hybrids.
- In vitro biological evaluation against TNBC cell lines (MDA-MB-231, MDA-MB-468).
- Cytotoxicity assays, apoptosis induction studies (caspase-mediated), and preliminary ADMET predictions.
Main Results:
- Compound 9h exhibited significant cytotoxic activity against MDA-MB-231 and MDA-MB-468 cells.
- 9h demonstrated superior potency compared to tamoxifen and comparable efficacy to cisplatin against MDA-MB-231 cells.
- Apoptosis assays confirmed that 9h induces cell death via the caspase pathway.
Conclusions:
- The novel triazolopyrimidine-isatin hybrid 9h is a promising candidate for TNBC treatment.
- Compound 9h exhibits potent anti-cancer activity through apoptosis induction.
- Further investigation into 9h as a potential TNBC therapeutic is warranted.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
